Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 3/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931865 | 1.00 | ENPP2 (0.32) | ENPP2PARP1PRMT5WDR77EGLN1 | |
| SCHEMBL29952025 | 0.90 | PRMT5 (0.39) | PRMT5WDR77CYP2A6BACE1CTSD | |
| SCHEMBL29957892 | 0.81 | GRM5 (0.31) | ENPP2GRM5 | |
| SCHEMBL9948434 | 0.80 | GRM5 (0.35) | ENPP2CYP2A6GRM5 | |
| SCHEMBL5742874 | 0.79 | GRM5 (0.38) | PARP1PRMT5WDR77EGLN1CYP2A6 | |
| SCHEMBL248711 | 0.76 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL15957833 | 0.74 | GRM5 (0.40) | PRMT5WDR77CYP2A6GRM5 | |
| SCHEMBL2381674 | 0.74 | — | — | |
| SCHEMBL28967087 | 0.73 | ENPP2 (0.36) | ENPP2 | |
| SCHEMBL21518938 | 0.73 | GRM5 (0.38) | PARP1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246981-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246981-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GGCT | ENPP2 479/4885PARP1 1325/4885PRMT5 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.